.jpg)
Texas outsourcer in Lilly's compounded tirzepatide lawsuit hit with FDA warning letter
The FDA has slapped Empower Pharma with a warning letter citing a laundry list of production issues that put the company in violation of its 503B compounding credentials under the Federal Food, Drug, and Cosmetic Act.
The FDA has slapped Empower Pharma with a warning letter citing a laundry list of production issues that put the company in violation of its 503B compounding credentials under the Federal Food, Drug, and Cosmetic Act.
